Infection risk among adults with down syndrome: a two group series of 101 patients in a tertiary center

Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in children. Little is known about immunity and infections in DS at adulthood. We studied two separate group of adults (> 18 years old) with DS...

Full description

Saved in:
Bibliographic Details
Published inOrphanet journal of rare diseases Vol. 14; no. 1; pp. 15 - 6
Main Authors Guffroy, Aurélien, Dieudonné, Yannick, Uring-Lambert, Beatrice, Goetz, Joelle, Alembik, Yves, Korganow, Anne-Sophie
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 11.01.2019
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in children. Little is known about immunity and infections in DS at adulthood. We studied two separate group of adults (> 18 years old) with DS in a single referral tertiary center (Strasbourg University Hospital). The first group included 37 ambulatory DS patients between November 2014 and May 2017. We analyzed exhaustive serological and immunobiological parameters, at one point, together with the prevalence of infections, autoimmune manifestations and malignancies. The second group included 64 hospitalized patients (138 stays) in the same center, between January 2005 and December 2016. One hundred and one adult patients with DS were included. Unlike children and despite a global lymphopenia, adults with DS underwent few infections in our ambulatory group. They did not experience any malignancy and, apart from hypothyroidism, they presented only occasional autoimmune manifestations. Hospitalized DS patients were older than ambulatory ones (median age 47 years (18-73) vs. 27 (18-52), p < 0.0001) and admitted mostly for infections (76.8%). Infections were associated with epilepsy and dementia (OR 6.5 (2.2-19), p = 0.001; p = 0.0006 in multivariate analysis) and higher mortality (OR 7.4 (1.4-37), p = 0.01). Despite persistent immunobiological abnormalities at adulthood, young ambulatory adults with DS remain healthy with a low rate of infections. Infections are associated with neurological degeneration and increase the mortality arguing for a dedicated support of older DS patients. ClinicalTrials.gov: NCT01663675 (August 13, 2012). Hospital Clinical Research Program (PHRC): number 2012-A00466-37 (Dr Y. Alembik).
AbstractList Background Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in children. Little is known about immunity and infections in DS at adulthood. Methods We studied two separate group of adults (> 18 years old) with DS in a single referral tertiary center (Strasbourg University Hospital). The first group included 37 ambulatory DS patients between November 2014 and May 2017. We analyzed exhaustive serological and immunobiological parameters, at one point, together with the prevalence of infections, autoimmune manifestations and malignancies. The second group included 64 hospitalized patients (138 stays) in the same center, between January 2005 and December 2016. Results One hundred and one adult patients with DS were included. Unlike children and despite a global lymphopenia, adults with DS underwent few infections in our ambulatory group. They did not experience any malignancy and, apart from hypothyroidism, they presented only occasional autoimmune manifestations. Hospitalized DS patients were older than ambulatory ones (median age 47 years (18–73) vs. 27 (18–52), p < 0.0001) and admitted mostly for infections (76.8%). Infections were associated with epilepsy and dementia (OR 6.5 (2.2–19), p = 0.001; p = 0.0006 in multivariate analysis) and higher mortality (OR 7.4 (1.4–37), p = 0.01). Conclusion Despite persistent immunobiological abnormalities at adulthood, young ambulatory adults with DS remain healthy with a low rate of infections. Infections are associated with neurological degeneration and increase the mortality arguing for a dedicated support of older DS patients. Trial registration ClinicalTrials.gov: NCT01663675 (August 13, 2012). Hospital Clinical Research Program (PHRC): number 2012-A00466–37 (Dr Y. Alembik).
Abstract Background Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in children. Little is known about immunity and infections in DS at adulthood. Methods We studied two separate group of adults (> 18 years old) with DS in a single referral tertiary center (Strasbourg University Hospital). The first group included 37 ambulatory DS patients between November 2014 and May 2017. We analyzed exhaustive serological and immunobiological parameters, at one point, together with the prevalence of infections, autoimmune manifestations and malignancies. The second group included 64 hospitalized patients (138 stays) in the same center, between January 2005 and December 2016. Results One hundred and one adult patients with DS were included. Unlike children and despite a global lymphopenia, adults with DS underwent few infections in our ambulatory group. They did not experience any malignancy and, apart from hypothyroidism, they presented only occasional autoimmune manifestations. Hospitalized DS patients were older than ambulatory ones (median age 47 years (18–73) vs. 27 (18–52), p < 0.0001) and admitted mostly for infections (76.8%). Infections were associated with epilepsy and dementia (OR 6.5 (2.2–19), p = 0.001; p = 0.0006 in multivariate analysis) and higher mortality (OR 7.4 (1.4–37), p = 0.01). Conclusion Despite persistent immunobiological abnormalities at adulthood, young ambulatory adults with DS remain healthy with a low rate of infections. Infections are associated with neurological degeneration and increase the mortality arguing for a dedicated support of older DS patients. Trial registration ClinicalTrials.gov: NCT01663675 (August 13, 2012). Hospital Clinical Research Program (PHRC): number 2012-A00466–37 (Dr Y. Alembik).
Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in children. Little is known about immunity and infections in DS at adulthood. We studied two separate group of adults (> 18 years old) with DS in a single referral tertiary center (Strasbourg University Hospital). The first group included 37 ambulatory DS patients between November 2014 and May 2017. We analyzed exhaustive serological and immunobiological parameters, at one point, together with the prevalence of infections, autoimmune manifestations and malignancies. The second group included 64 hospitalized patients (138 stays) in the same center, between January 2005 and December 2016. One hundred and one adult patients with DS were included. Unlike children and despite a global lymphopenia, adults with DS underwent few infections in our ambulatory group. They did not experience any malignancy and, apart from hypothyroidism, they presented only occasional autoimmune manifestations. Hospitalized DS patients were older than ambulatory ones (median age 47 years (18-73) vs. 27 (18-52), p < 0.0001) and admitted mostly for infections (76.8%). Infections were associated with epilepsy and dementia (OR 6.5 (2.2-19), p = 0.001; p = 0.0006 in multivariate analysis) and higher mortality (OR 7.4 (1.4-37), p = 0.01). Despite persistent immunobiological abnormalities at adulthood, young ambulatory adults with DS remain healthy with a low rate of infections. Infections are associated with neurological degeneration and increase the mortality arguing for a dedicated support of older DS patients.
Background Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in children. Little is known about immunity and infections in DS at adulthood. Methods We studied two separate group of adults (> 18 years old) with DS in a single referral tertiary center (Strasbourg University Hospital). The first group included 37 ambulatory DS patients between November 2014 and May 2017. We analyzed exhaustive serological and immunobiological parameters, at one point, together with the prevalence of infections, autoimmune manifestations and malignancies. The second group included 64 hospitalized patients (138 stays) in the same center, between January 2005 and December 2016. Results One hundred and one adult patients with DS were included. Unlike children and despite a global lymphopenia, adults with DS underwent few infections in our ambulatory group. They did not experience any malignancy and, apart from hypothyroidism, they presented only occasional autoimmune manifestations. Hospitalized DS patients were older than ambulatory ones (median age 47 years (18-73) vs. 27 (18-52), p < 0.0001) and admitted mostly for infections (76.8%). Infections were associated with epilepsy and dementia (OR 6.5 (2.2-19), p = 0.001; p = 0.0006 in multivariate analysis) and higher mortality (OR 7.4 (1.4-37), p = 0.01). Conclusion Despite persistent immunobiological abnormalities at adulthood, young ambulatory adults with DS remain healthy with a low rate of infections. Infections are associated with neurological degeneration and increase the mortality arguing for a dedicated support of older DS patients. Trial registration ClinicalTrials.gov: NCT01663675 (August 13, 2012). Hospital Clinical Research Program (PHRC): number 2012-A00466-37 (Dr Y. Alembik). Keywords: Down syndrome, Immunodeficiency, Infectious risk, Neurological impairment, Adult
Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in children. Little is known about immunity and infections in DS at adulthood. We studied two separate group of adults (> 18 years old) with DS in a single referral tertiary center (Strasbourg University Hospital). The first group included 37 ambulatory DS patients between November 2014 and May 2017. We analyzed exhaustive serological and immunobiological parameters, at one point, together with the prevalence of infections, autoimmune manifestations and malignancies. The second group included 64 hospitalized patients (138 stays) in the same center, between January 2005 and December 2016. One hundred and one adult patients with DS were included. Unlike children and despite a global lymphopenia, adults with DS underwent few infections in our ambulatory group. They did not experience any malignancy and, apart from hypothyroidism, they presented only occasional autoimmune manifestations. Hospitalized DS patients were older than ambulatory ones (median age 47 years (18-73) vs. 27 (18-52), p < 0.0001) and admitted mostly for infections (76.8%). Infections were associated with epilepsy and dementia (OR 6.5 (2.2-19), p = 0.001; p = 0.0006 in multivariate analysis) and higher mortality (OR 7.4 (1.4-37), p = 0.01). Despite persistent immunobiological abnormalities at adulthood, young ambulatory adults with DS remain healthy with a low rate of infections. Infections are associated with neurological degeneration and increase the mortality arguing for a dedicated support of older DS patients. ClinicalTrials.gov: NCT01663675 (August 13, 2012). Hospital Clinical Research Program (PHRC): number 2012-A00466-37 (Dr Y. Alembik).
Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in children. Little is known about immunity and infections in DS at adulthood.BACKGROUNDDown syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in children. Little is known about immunity and infections in DS at adulthood.We studied two separate group of adults (> 18 years old) with DS in a single referral tertiary center (Strasbourg University Hospital). The first group included 37 ambulatory DS patients between November 2014 and May 2017. We analyzed exhaustive serological and immunobiological parameters, at one point, together with the prevalence of infections, autoimmune manifestations and malignancies. The second group included 64 hospitalized patients (138 stays) in the same center, between January 2005 and December 2016.METHODSWe studied two separate group of adults (> 18 years old) with DS in a single referral tertiary center (Strasbourg University Hospital). The first group included 37 ambulatory DS patients between November 2014 and May 2017. We analyzed exhaustive serological and immunobiological parameters, at one point, together with the prevalence of infections, autoimmune manifestations and malignancies. The second group included 64 hospitalized patients (138 stays) in the same center, between January 2005 and December 2016.One hundred and one adult patients with DS were included. Unlike children and despite a global lymphopenia, adults with DS underwent few infections in our ambulatory group. They did not experience any malignancy and, apart from hypothyroidism, they presented only occasional autoimmune manifestations. Hospitalized DS patients were older than ambulatory ones (median age 47 years (18-73) vs. 27 (18-52), p < 0.0001) and admitted mostly for infections (76.8%). Infections were associated with epilepsy and dementia (OR 6.5 (2.2-19), p = 0.001; p = 0.0006 in multivariate analysis) and higher mortality (OR 7.4 (1.4-37), p = 0.01).RESULTSOne hundred and one adult patients with DS were included. Unlike children and despite a global lymphopenia, adults with DS underwent few infections in our ambulatory group. They did not experience any malignancy and, apart from hypothyroidism, they presented only occasional autoimmune manifestations. Hospitalized DS patients were older than ambulatory ones (median age 47 years (18-73) vs. 27 (18-52), p < 0.0001) and admitted mostly for infections (76.8%). Infections were associated with epilepsy and dementia (OR 6.5 (2.2-19), p = 0.001; p = 0.0006 in multivariate analysis) and higher mortality (OR 7.4 (1.4-37), p = 0.01).Despite persistent immunobiological abnormalities at adulthood, young ambulatory adults with DS remain healthy with a low rate of infections. Infections are associated with neurological degeneration and increase the mortality arguing for a dedicated support of older DS patients.CONCLUSIONDespite persistent immunobiological abnormalities at adulthood, young ambulatory adults with DS remain healthy with a low rate of infections. Infections are associated with neurological degeneration and increase the mortality arguing for a dedicated support of older DS patients.ClinicalTrials.gov: NCT01663675 (August 13, 2012). Hospital Clinical Research Program (PHRC): number 2012-A00466-37 (Dr Y. Alembik).TRIAL REGISTRATIONClinicalTrials.gov: NCT01663675 (August 13, 2012). Hospital Clinical Research Program (PHRC): number 2012-A00466-37 (Dr Y. Alembik).
ArticleNumber 15
Audience Academic
Author Korganow, Anne-Sophie
Guffroy, Aurélien
Uring-Lambert, Beatrice
Alembik, Yves
Dieudonné, Yannick
Goetz, Joelle
Author_xml – sequence: 1
  givenname: Aurélien
  orcidid: 0000-0003-0615-5305
  surname: Guffroy
  fullname: Guffroy, Aurélien
– sequence: 2
  givenname: Yannick
  surname: Dieudonné
  fullname: Dieudonné, Yannick
– sequence: 3
  givenname: Beatrice
  surname: Uring-Lambert
  fullname: Uring-Lambert, Beatrice
– sequence: 4
  givenname: Joelle
  surname: Goetz
  fullname: Goetz, Joelle
– sequence: 5
  givenname: Yves
  surname: Alembik
  fullname: Alembik, Yves
– sequence: 6
  givenname: Anne-Sophie
  surname: Korganow
  fullname: Korganow, Anne-Sophie
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30634988$$D View this record in MEDLINE/PubMed
BookMark eNp1kktv1DAUhSNURB_wA9ggS2xgkXL9SGKzqFRVPEaqhMRjbTmOnXpI7MFOmPbf4zAtdCqQF7FuvnPu9dU5Lg588KYonmM4xZjXbxKmQGgJmJcguCivHxVHuKmgxLghB_fuh8VxSmsAVlHgT4pDCjVlgvOjol95a_TkgkfRpe9IjcH3SHXzMCW0ddMV6sLWo3TjuxhG8xYpNG0D6mOYNyiZ6ExCwSIMGG3U5IzPMucXysTJqXiDdK6Z-LR4bNWQzLPb70nx7f27rxcfy8tPH1YX55elrgmfyqZrNQbGBNaEUgyiI1ULLSFMa6oaVpO67gAbayoGCkOL27ahFgg0Fqi29KRY7Xy7oNZyE92YZ5BBOfm7EGIvVR5MD0bmPla3tOICGpY7iY5bBR3B1lrOic5eZzuvzdyOplseEtWwZ7r_x7sr2YefsqZEgBDZ4NWtQQw_ZpMmObqkzTAob8KcJMGNoBVjjGb05QN0Hebo86oyVfMaWI3ZX6pX-QHO25D76sVUnlccM2BU1Jk6_QeVT2dGp3OErMv1PcHrPUFmJnM99WpOSa6-fN5nX9xfyp9t3EUqA80O0DGkFI2V2k1qSViewg157XIJr9yFV-bwyiW88jor8QPlnfn_Nb8AIlruiA
CitedBy_id crossref_primary_10_1007_s00281_020_00804_1
crossref_primary_10_1590_1516_3180_2023_0015_r1_230523
crossref_primary_10_3389_fimmu_2021_621440
crossref_primary_10_1016_j_arr_2021_101541
crossref_primary_10_1007_s12017_021_08651_5
crossref_primary_10_1007_s11686_021_00473_6
crossref_primary_10_3389_fimmu_2020_00840
crossref_primary_10_1007_s10875_020_00805_7
crossref_primary_10_1016_j_vaccine_2023_05_063
Cites_doi 10.1016/j.vaccine.2013.09.070
10.1080/714037692
10.1016/S0140-6736(03)12987-X
10.1016/j.jaci.2014.07.015
10.1158/1055-9965.EPI-14-1181
10.1038/ejhg.2008.122
10.1016/S0140-6736(02)08092-3
10.1093/infdis/jix168
10.1203/PDR.0b013e3181d4ecc1
10.1136/bmj.g5596
10.1002/eji.201445049
10.1016/S1474-4422(10)70112-5
10.1006/clin.1996.0031
10.1097/INF.0b013e3182737410
10.1097/INF.0b013e3181ff85a8
10.4049/jimmunol.1001700
10.1016/S0140-6736(99)05264-2
10.1016/j.braindev.2004.07.008
10.1002/ajmg.a.35706
10.1016/j.micinf.2010.05.007
10.1111/j.1365-2249.2011.04335.x
10.1016/j.jpeds.2009.12.006
ContentType Journal Article
Copyright COPYRIGHT 2019 BioMed Central Ltd.
Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s). 2019
Copyright_xml – notice: COPYRIGHT 2019 BioMed Central Ltd.
– notice: Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s). 2019
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AN0
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s13023-018-0989-x
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database



MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1750-1172
EndPage 6
ExternalDocumentID oai_doaj_org_article_104fcb358907409d9d8fa0d21fff882c
PMC6329099
A581404396
30634988
10_1186_s13023_018_0989_x
Genre Letter
Research Support, Non-U.S. Gov't
Correspondence
Letter to the Editor
GrantInformation_xml – fundername: Ministère des Affaires Sociales et de la Santé
  grantid: PHRC 2012-A00466-37
– fundername: Union Européenne
  grantid: This work was supported by grants from EU-funded (ERDF) project INTERREG V "RARENET".
– fundername: ;
  grantid: This work was supported by grants from EU-funded (ERDF) project INTERREG V “RARENET”.
– fundername: ;
  grantid: PHRC 2012-A00466-37
GroupedDBID ---
0R~
123
29N
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AN0
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BNQBC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ISR
ITC
KQ8
M1P
M48
MK0
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
~8M
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c628t-7dbc104491c233109d25b0b224cc3a746266d01efe540a10b1bb73f0207f03cf3
IEDL.DBID M48
ISSN 1750-1172
IngestDate Wed Aug 27 01:32:16 EDT 2025
Thu Aug 21 18:41:50 EDT 2025
Fri Jul 11 09:12:41 EDT 2025
Fri Jul 25 22:33:42 EDT 2025
Tue Jun 17 21:46:29 EDT 2025
Tue Jun 10 20:29:01 EDT 2025
Fri Jun 27 04:22:31 EDT 2025
Thu Jan 02 22:59:17 EST 2025
Tue Jul 01 02:23:24 EDT 2025
Thu Apr 24 22:57:12 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Neurological impairment
Adult
Down syndrome
Infectious risk
Immunodeficiency
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c628t-7dbc104491c233109d25b0b224cc3a746266d01efe540a10b1bb73f0207f03cf3
Notes SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 14
ObjectType-Letter to the Editor-1
ObjectType-Article-2
ObjectType-Correspondence-1
content type line 23
ORCID 0000-0003-0615-5305
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13023-018-0989-x
PMID 30634988
PQID 2168604614
PQPubID 76088
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_104fcb358907409d9d8fa0d21fff882c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6329099
proquest_miscellaneous_2179354443
proquest_journals_2168604614
gale_infotracmisc_A581404396
gale_infotracacademiconefile_A581404396
gale_incontextgauss_ISR_A581404396
pubmed_primary_30634988
crossref_citationtrail_10_1186_s13023_018_0989_x
crossref_primary_10_1186_s13023_018_0989_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-01-11
PublicationDateYYYYMMDD 2019-01-11
PublicationDate_xml – month: 01
  year: 2019
  text: 2019-01-11
  day: 11
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Orphanet journal of rare diseases
PublicationTitleAlternate Orphanet J Rare Dis
PublicationYear 2019
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References E Cuadrado (989_CR13) 1996; 78
BLP Bloemers (989_CR14) 2010; 12
989_CR19
C Irving (989_CR1) 2008; 16
AM Linabery (989_CR18) 2015; 24
MA Kusters (989_CR9) 2012; 31
Q Yang (989_CR17) 2002; 359
M a A Kusters (989_CR8) 2013; 31
RHJ Verstegen (989_CR22) 2010; 67
NJ Roizen (989_CR16) 2003; 361
JE Ming (989_CR12) 2003; 40
J Schoch (989_CR7) 2017; 215
IT Lott (989_CR23) 2010; 9
A Englund (989_CR4) 2013; 161
R Carsetti (989_CR21) 2015; 45
MA Kusters (989_CR10) 2011; 30
H Hasle (989_CR15) 2000; 355
BLP Bloemers (989_CR20) 2011; 186
M Menéndez (989_CR24) 2005; 27
KM Jensen (989_CR2) 2014; 349
MA Kusters (989_CR11) 2011; 30
G Ram (989_CR5) 2011; 164
RHJ Verstegen (989_CR6) 2014; 134
989_CR3
References_xml – volume: 31
  start-page: 6261
  year: 2013
  ident: 989_CR8
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2013.09.070
– volume: 40
  start-page: 587
  year: 2003
  ident: 989_CR12
  publication-title: Crit Rev Clin Lab Sci
  doi: 10.1080/714037692
– volume: 361
  start-page: 1281
  year: 2003
  ident: 989_CR16
  publication-title: Lancet
  doi: 10.1016/S0140-6736(03)12987-X
– volume: 134
  start-page: 1346
  year: 2014
  ident: 989_CR6
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2014.07.015
– volume: 30
  start-page: 818
  year: 2011
  ident: 989_CR10
  publication-title: Decreased response after conjugated meningococcal serogroup C vaccination in children with Down syndrome Pediatr Infect Dis J
– volume: 24
  start-page: 454
  year: 2015
  ident: 989_CR18
  publication-title: Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol
  doi: 10.1158/1055-9965.EPI-14-1181
– volume: 16
  start-page: 1336
  year: 2008
  ident: 989_CR1
  publication-title: Eur J Hum Genet
  doi: 10.1038/ejhg.2008.122
– volume: 359
  start-page: 1019
  year: 2002
  ident: 989_CR17
  publication-title: Lancet Lond Engl.
  doi: 10.1016/S0140-6736(02)08092-3
– ident: 989_CR3
– volume: 215
  start-page: 1619
  year: 2017
  ident: 989_CR7
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jix168
– volume: 67
  start-page: 563
  year: 2010
  ident: 989_CR22
  publication-title: Pediatr Res
  doi: 10.1203/PDR.0b013e3181d4ecc1
– volume: 349
  start-page: g5596
  year: 2014
  ident: 989_CR2
  publication-title: BMJ
  doi: 10.1136/bmj.g5596
– volume: 45
  start-page: 903
  year: 2015
  ident: 989_CR21
  publication-title: Eur J Immunol
  doi: 10.1002/eji.201445049
– volume: 9
  start-page: 623
  year: 2010
  ident: 989_CR23
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(10)70112-5
– volume: 78
  start-page: 209
  year: 1996
  ident: 989_CR13
  publication-title: Clin Immunol Immunopathol
  doi: 10.1006/clin.1996.0031
– volume: 31
  start-page: 1284
  year: 2012
  ident: 989_CR9
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/INF.0b013e3182737410
– volume: 30
  start-page: 357
  year: 2011
  ident: 989_CR11
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/INF.0b013e3181ff85a8
– volume: 186
  start-page: 4500
  year: 2011
  ident: 989_CR20
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1001700
– volume: 355
  start-page: 165
  year: 2000
  ident: 989_CR15
  publication-title: Lancet Lond Engl
  doi: 10.1016/S0140-6736(99)05264-2
– volume: 27
  start-page: 246
  year: 2005
  ident: 989_CR24
  publication-title: Brain and Development
  doi: 10.1016/j.braindev.2004.07.008
– volume: 161
  start-page: 642
  year: 2013
  ident: 989_CR4
  publication-title: Am J Med Genet A
  doi: 10.1002/ajmg.a.35706
– volume: 12
  start-page: 799
  year: 2010
  ident: 989_CR14
  publication-title: Microbes Infect Inst Pasteur
  doi: 10.1016/j.micinf.2010.05.007
– volume: 164
  start-page: 9
  year: 2011
  ident: 989_CR5
  publication-title: Clin Exp Immunol
  doi: 10.1111/j.1365-2249.2011.04335.x
– ident: 989_CR19
  doi: 10.1016/j.jpeds.2009.12.006
SSID ssj0045308
Score 2.2840908
Snippet Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in...
Background Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and...
Abstract Background Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 15
SubjectTerms Adolescent
Adult
Adults
Age
Aged
Analysis
Cancer
Child health
Children
Chromosome Aberrations
Clinical trials
Congenital diseases
Degeneration
Dementia
Dementia disorders
Down syndrome
Down Syndrome - genetics
Down Syndrome - immunology
Down Syndrome - metabolism
Down's syndrome
Elderly patients
Epilepsy
Female
Hospitalization
Hospitals
Humans
Hypothyroidism
Immune system
Immunodeficiency
Infection
Infectious risk
Letter to the Editor
Lymphocytes
Lymphocytopenia
Lymphopenia
Lymphopenia - genetics
Lymphopenia - immunology
Lymphopenia - metabolism
Male
Malignancy
Medical research
Memory
Middle Aged
Mortality
Multivariate analysis
Neurological impairment
Rare diseases
Recurrence (Disease)
Retrospective Studies
Risk factors
Streptococcus infections
Tetanus
Thyroid hormones
Young Adult
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9UwFA4yC3Ejvq2OEkUQhGLaPJq4G8VhRtCFOjC7kOYxDkgrt_fi-O89J8293CLoxm1zAu05J-fRfPlCyAvVBC6T8nWMTtSiDaw2QUKrIrUXRkvmXEZbfFInZ-LDuTzfu-oLMWEzPfCsOFjVIvmeS41dHDPBBJ0cC22TUoLq0GP0hZy3babmGCwkZ7rsYTZavZ5wew5xQ7jVr019tchCmaz_z5C8l5OWeMm9BHR8i9wslSM9mt_4NrkWhzvk-seyN36XXJwWXNVAES9O8zVCNPNrTBR_t9IAHTfdUhS8oY6uf440H-ug6IhxomOisHhoIVud6OWAUgi9dqtfFF8sru6Rs-P3X9-d1OUahdqrVq_rLvQetChM41uORKChlT3rIXd7z10noKVRgTUxRajeXMP6pu87nqCO7BLjPvH75GAYh_gQD3h7JYXTvPdReBdM7JxJJijDJYPpFWFbtVpfOMbxqovvNvcaWtnZEhYsYdES9qoir3ZTfswEG38Tfou22gkiN3Z-AB5ji8fYf3lMRZ6jpS2yXwwIr7lwm2myp18-2yOpM92QURV5WYTSCF_gXTmtAHpAwqyF5OFCEpanXw5vHcqW8DDZtlFaIdU9aOzZbhhnIuRtiOMGZSB0SiEEr8iD2f923w19HoeVpCvSLTxzoZjlyHD5LZOHK94a6Aoe_Q9NPiY3oH5EvF3dNIfkYL3axCdQo637p3k5_gZp1Dek
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifls9JYogCOXa5qOJL3KKx52gD-rBvoU0H-uBtOd2F8__3plstl4R7rWZQJP5yExm8htCXsnaMxGlK0OwvOSNr0rtBYQqQjmulaisTdUWX-TxKf-0EIt84TbmssqdTUyG2g8O78gPmloqiejg_N35rxK7RmF2NbfQuE5uIHQZSnW7mAIuLlilciazVvJgxCQdVg9hwl_p8mJ2FiXI_v8N86WTaV41eekYOrpDbmf_kR5uGX6XXAv9PXLzc86Q3yfLk1xd1VOsGqepmRBNKBsjxUtX6iHupjuggrfU0vXvgabHHRTFMYx0iBRUiGbI1ZGe9UiFBdh29Yfij4XVA3J69PH7h-MyN1MonWzUumx95yD04rp2DUM4UN-IrurgBHeO2ZZDYCN9VYcYwIezddXVXdeyCN5kGyvmIntI9vqhD4_xmbeTglvFOhe4s16H1uqovdRMVDC9INVuW43LSOPY8OKnSRGHkmbLCQOcMMgJc1GQN9OU8y3MxlXE75FXEyEiZKcPw2ppssLBbB5dx4TC6B9Wq72KtvJNHWOEqMIV5CVy2iAGRo9FNku7GUdz8u2rORQqgQ5pWZDXmSgOsAJn85sF2AeEzZpR7s8oQUndfHgnUCYbidH8E-mCvJiGcSYWvvVh2CANGFDBOWcFebSVv2ndEO0x0CdVkHYmmbONmY_0Zz8ShLhkjYbY4MnVv_WU3AL_EOvpyrreJ3vr1SY8Ax9s3T1PivYXsLEu9g
  priority: 102
  providerName: ProQuest
Title Infection risk among adults with down syndrome: a two group series of 101 patients in a tertiary center
URI https://www.ncbi.nlm.nih.gov/pubmed/30634988
https://www.proquest.com/docview/2168604614
https://www.proquest.com/docview/2179354443
https://pubmed.ncbi.nlm.nih.gov/PMC6329099
https://doaj.org/article/104fcb358907409d9d8fa0d21fff882c
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEF9qC-KL-G20HqsIghBNsh_ZFUSu0tIetEjrQd-WzWb3LJREL3fY_vfO7OWOBotPPgWyM5Cd2cnM7M7-hpC3Mq-ZCNKl3lue8qLOUl0LSFWEclwrkVkbqy1O5OGUT87F-RZZt7fqBdjdmtphP6np_PLD1a_rL2Dwn6PBK_mxw8M3rArCg3ylUwgpd8AxldjQ4JhvDhW4YJnqDzZvZRu4pojg__d_-oajGhZR3vBKBw_I_T6cpOOV_h-SLd88IneP-wPzx2R21BdbNRSLyGnsLUQj6EZHcQ-W1pCG0zVuwSdq6eJ3S-NdD4qr03e0DRQsivYIrB29aJAK67Ht_Jrih_n5EzI92P_-9TDteyukThZqkZZ15SAT4zp3BUN00LoQVVaBQ3eO2ZJDniPrLPfBQ0hn86zKq6pkAYLLMmTMBfaUbDdt45_jrW8nBbeKVc5zZ2vtS6uDrqVmIgP2hGRrsRrXA49j_4tLExMQJc1KEwY0YVAT5ioh7zcsP1eoG_8i3kNdbQgRMDu-aOcz09sfcPPgKiYUbgbAbHWtgs3qIg8hQJLhEvIGNW0QEqPBmpuZXXadOTo7NWOhIgaRlgl51xOFFmbgbH-FAeSAKFoDyt0BJdisGw6vF5RZL3lT5FJJxL8Hib3eDCMn1sE1vl0iDfxPBeecJeTZav1t5g3JHwPzUgkpBytzIJjhSHPxIyKKS1ZoSBVe_A9JviT3IKjEIrw0z3fJ9mK-9K8gcFtUI3KnPC9HZGc8npxN4Lm3f_LtdBS3QUbRVP8ACyREVA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELZKkYAXxE2ggEEgJKSoSXzEQUKoHNUuPR6glfbNdXwslVBSNrtq-6f4jcxkk6URUt_6uh6vYs9tj78h5LVMHRNB2th7w2OeuSQunIBURSjLCyUSY9pqi305OuTfJmKyRv70b2GwrLK3ia2hdrXFM_LNLJVKIjo4_3jyO8auUXi72rfQWIrFjj8_hZSt-TD-Avx9k2XbXw8-j-Kuq0BsZabmce5KCzkIL1KbMcTFdJkokxJcmbXM5BwifOmS1AcPwYxJkzIty5wFCKvykDAbGPzvNXIdHG-CyV4-WSV4XLBEdTenqZKbDV4KYrUSFhioIj4b-L62RcD_juCCJxxWaV5we9t3yO0uXqVbSwG7S9Z8dY_c2Otu5O-T6bir5qooVqnTtnkRbVE9GoqHvNRBnk97YIT31ND5aU3bxyQUxd83tA4UVJZ2EK8NPa6QCgu-zeyc4of52QNyeCXb_JCsV3XlH-OzcisFN4qV1nNrXOFzU4TCyYKJBKZHJOm3VdsO2RwbbPzSbYajpF5yQgMnNHJCn0Xk3WrKyRLW4zLiT8irFSEicrc_1LOp7hQcZvNgSyYUnjbAagungklcloYQIIuxEXmFnNaIuVFhUc_ULJpGj39811tCtSBHhYzI244o1LACa7o3ErAPCNM1oNwYUIJRsMPhXqB0Z5Qa_U-FIvJyNYwzsdCu8vUCacBgC845i8ijpfyt1g3ZJQP9VRHJB5I52JjhSHX8s4UslywrIBd5cvlnvSA3Rwd7u3p3vL_zlNyC2BRr-eI03SDr89nCP4P4b14-b5WOkqOr1vK_5M5qZw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Infection+risk+among+adults+with+down+syndrome%3A+a+two+group+series+of+101+patients+in+a+tertiary+center&rft.jtitle=Orphanet+journal+of+rare+diseases&rft.au=Aur%C3%A9lien+Guffroy&rft.au=Yannick+Dieudonn%C3%A9&rft.au=Beatrice+Uring-Lambert&rft.au=Joelle+Goetz&rft.date=2019-01-11&rft.pub=BMC&rft.eissn=1750-1172&rft.volume=14&rft.issue=1&rft.spage=1&rft.epage=6&rft_id=info:doi/10.1186%2Fs13023-018-0989-x&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_104fcb358907409d9d8fa0d21fff882c
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1172&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1172&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1172&client=summon